Onureg (Azacitidine) for Leukemia

Overview
Onureg is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat adults with acute myeloid leukemia who achieved a first complete remission or complete remission with incomplete blood count recovery following intensive induction chemotherapy and are not able to complete intensive curative therapy. Onureg is also known by its drug name, Azacitidine.

Onureg is an anticancer drug used in chemotherapy. Onureg is a nucleoside metabolic inhibitor. Onureg is believed to work by damaging DNA and preventing the formation of cancer cells.

How do I take it?
Onureg is taken once daily on the first through the 14th days of a 28-day cycle.

Onureg is taken in tablet form.

Side effects
The FDA-approved label for Onureg lists common side effects including nausea, vomiting, fatigue, constipation, pneumonia, abdominal pain, decreased appetite, dizziness, and pain in the extremities.

Rare but serious side effects listed for Onureg include low white blood cell counts, low platelet counts, and fetal harm in pregnant women.

For more details about this treatment, visit:

Onureg — Bristol Myers Squibb
www.onuregpro.com